Clinical Trials Logo

Metaplasia clinical trials

View clinical trials related to Metaplasia.

Filter by:

NCT ID: NCT06370143 Recruiting - Gastric Cancer Clinical Trials

A Study Collecting Health Information to Understand and Prevent Gastric Cancer

Start date: April 11, 2024
Phase:
Study type: Observational

The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.

NCT ID: NCT06282484 Completed - Gastric Cancer Clinical Trials

A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions

Start date: September 1, 2022
Phase:
Study type: Observational

To explore the effects of gastric xanthoma on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer.

NCT ID: NCT06269380 Completed - Clinical trials for Intestinal Metaplasia

Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy

Start date: February 13, 2024
Phase: N/A
Study type: Interventional

Esophagogastroduodenoscopy (EGD) is commonly performed in patients presenting with abdominal pain and dyspeptic symptoms, serving as a valuable diagnostic and therapeutic tool. While various methods are available for biopsy sampling when mucosal pathology is observed during EGD, the practice of obtaining biopsies from endoscopically normal mucosa remains controversial. Although there is literature suggesting that routine biopsies from the antrum and duodenum for surveillance purposes increase costs, pathological findings can sometimes be detected in areas that appear normal on mucosal examination, leading to potential changes in treatment approach if biopsies are obtained. In this study, a retrospective evaluation of the prevalence of various pathologies detected in biopsies obtained from endoscopically normal mucosa in patients who underwent EGD was reported as normal.

NCT ID: NCT06085677 Not yet recruiting - Stomach Neoplasm Clinical Trials

The Gastric HormonE BioMarkers of Preneoplastic Lesions Study

GEM
Start date: November 4, 2023
Phase:
Study type: Observational

The goal of the study is to understand whether blood levels of hormones produced or metabolized in the stomach reflect the health of the stomach lining. Specifically the study will determine whether the concentration of ghrelin, gastrin, pepsinogens and vitamin B12 reflect the condition of the stomach lining. Hormone concentrations for people with normal/mild gastritis will be compared to people with long-term inflammation of the stomach (chronic atrophic gastritis), and people with pre-cancerous cellular changes (intestinal metaplasia).

NCT ID: NCT06075199 Recruiting - Clinical trials for Intestinal Metaplasia of Gastric Mucosa

Intestinal Metaplasia Cohort for Gastric Cancer Prediction

Start date: September 13, 2023
Phase:
Study type: Observational [Patient Registry]

In this study, we aim to establish a prospective cohort of patients with endoscopically and histologically confirmed intestinal metaplasia, collect gastric mucosal tissue samples from this cohort, and follow the development of gastric cancer over time.

NCT ID: NCT06035029 Recruiting - Appendicitis Clinical Trials

Intestinal Flora and Metabonomics of Appendicitis

Start date: April 3, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the key bacterial flora and metabolites associated with appendicitis in children. The main questions it aims to answer are: - To screen out the key biomarkers of pediatric appendicitis. - What are the microbial differences in different parts of pediatric appendicitis patients. Participants will detect feces using 16s ribosomal RiboNucleicAcid (16S rRNA) gene sequencing technology and differences of the fecal metabolites between healthy children and appendicitis children were analyzed using untargeted metabolomics based on Liquid chromatography-tandem mass spectrometry(LC-M S/MS) platform.Through the analysis of intestinal bacterial flora and metabolomics association and the differential analysis of intestinal bacterial flora in different parts of the case group, the key bacterial flora and metabolites were excavated.

NCT ID: NCT05818072 Recruiting - Barrett's Esophagus Clinical Trials

The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE

Start date: March 13, 2023
Phase: N/A
Study type: Interventional

Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.

NCT ID: NCT05782465 Active, not recruiting - Stomach Neoplasm Clinical Trials

Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)

Start date: August 23, 2019
Phase:
Study type: Observational

This study is carried out to find out if a customized molecular test can identify a subgroup of patients with very-high-risk of developing stomach cancer within patients with intestinal metaplasia (IM). The investigators hypothesise that the incidence of dysplasia and GC cases in the molecular-test-positive group will be significantly higher than that in the molecular-test-negative group. Such a test has the potential to guide clinicians to better manage patients with IM by allowing endoscopic surveillance to be focused on individuals at very-high-risk of developing stomach cancer, at the same time avoiding or reducing endoscopies for those at lower risk.

NCT ID: NCT05657080 Recruiting - Gastric Cancer Clinical Trials

Cytosponge for Gastric Intestinal Metaplasia

CyGIM
Start date: October 16, 2023
Phase:
Study type: Observational

Gastric cancer has a very poor prognosis. The disease is often diagnosed at a late stage, when curative treatment options are limited or ineffective. There is a condition that predisposes to gastric cancer, known in medical terms as Gastric intestinal metaplasia (GIM). This pre-cancerous condition can be diagnosed with an endoscopic camera test, but it often very subtle and can be missed at routine endoscopy. There is evidence that about 7% of gastric cancers are missed at previous endoscopy. The Cytosponge-trefoil factor 3 (TFF-3) is a pill on a string combined to a molecular biomarker which could help early diagnosis of gastric cancer and GIM. Cytosponge-TFF3 has been showed in previous research to be useful to diagnose Barrett's oesophagus, a condition of the food pipe similar to GIM. The aim of this study is to investigate the utility of the Cytosponge in combination with molecular biomakers to diagnose GIM

NCT ID: NCT05631015 Active, not recruiting - Gastric Cancer Clinical Trials

Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals

Start date: January 1, 2012
Phase:
Study type: Observational

The purpose of this study is to develop and validate a clinical decision support system based on automated algorithms. This system can use natural language processing to extract data from patients' endoscopic reports and pathological reports, identify patients' disease types and grades, and generate guidelines based follow-up or treatment recommendations